In pharmaceutical development, sponsors often focus heavily on clinical milestones, toxicology readiness, or formulation strategy. But long before those activities begin, critical decisions are already being made at the API level that can dramatically impact cost, scalability, timelines, and long-term manufacturability.
According to Olon USA CEO Robert Poe, the most successful programs are typically the ones that begin thinking about scale-up, formulation compatibility, and downstream manufacturing much earlier than expected.
Early API Decisions Shape Everything Downstream
One of the biggest misconceptions in drug development is that API manufacturing simply produces material for the next phase of development.
In reality, API strategy influences nearly every downstream decision.
At Olon USA, development teams evaluate not only how to manufacture a compound today, but how the process will scale from milligrams to grams, kilograms, and eventually commercial-scale manufacturing.
That forward-thinking approach helps sponsors avoid expensive redevelopment later.
For example, purification techniques that work effectively at small scale may become highly inefficient at larger volumes. Certain chromatography steps can reduce yield significantly during scale-up, forcing sponsors to redesign manufacturing processes midway through development.
Identifying those challenges early can save substantial time and money.
Reducing Redundant Manufacturing Costs
Early coordination can also prevent unnecessary manufacturing duplication.
Poe described a recent example involving a sponsor reviving a shelved API for a new indication. Initially, the sponsor planned to manufacture separate batches for toxicology studies and Phase 1 clinical work.
Instead, Olon USA recommended producing a larger unified batch and strategically reserving material for tox studies before final purification.
Because the material originated from the same process stream, the sponsor avoided introducing new impurities while significantly reducing manufacturing costs.
That type of guidance often becomes possible only when API teams are engaged early enough to understand the sponsor’s broader development plan.
Pre-Formulation Work Matters More Than Many Sponsors Realize
API development and formulation strategy are also closely interconnected.
Olon USA’s analytical teams perform extensive pre-formulation evaluations designed to identify potential compatibility issues, polymorph considerations, excipient interactions, and stability risks before formulation work begins.
Those early studies can help sponsors:
- Improve absorption potential
- Increase formulation stability
- Avoid incompatible excipients
- Better understand active polymorph behavior
- Reduce unnecessary API waste
- Optimize final dosage forms
In some cases, understanding the correct polymorph early can directly impact final dose requirements, capsule size, tablet design, and overall formulation efficiency.
Sponsors Often Underestimate Material Requirements
Another common challenge is simply calculating how much API material will actually be required.
Sponsors may initially estimate quantities based only on dosing needs, overlooking additional requirements for analytical testing, stability studies, retains, microbiology testing, and reserve samples.
Those gaps can create costly delays if additional material must later be manufactured under compressed timelines.
By involving API experts earlier, sponsors gain more accurate forecasting and stronger alignment across the full development program.
Coordinated Programs Move Faster
Ultimately, the goal of a central CMC strategy is not simply better communication. It is development efficiency.
When API developers, tox partners, analytical teams, and formulation groups all operate from the same timeline expectations, sponsors are far less likely to experience preventable delays, idle manufacturing time, or expensive scheduling disruptions.
For growing biotech companies navigating increasingly aggressive development timelines, that coordination can become a major competitive advantage.
And according to Olon USA, it all starts earlier than many sponsors think.